stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) Revenue
Rhythm Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $189.8M, up 45.8% from $130.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $280.7M. Over the past ten years it has ranged from $3.2M (fiscal 2021) to $189.8M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Rhythm Pharmaceuticals, Inc. ranks 60th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $189.8M | 45.83% |
| FY2024 | $130.1M | 68.06% |
| FY2023 | $77.4M | 227.56% |
| FY2022 | $23.6M | 649.46% |
| FY2021 | $3.2M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $92.1M | 29.29% |
| Jun 2026 | $71.3M | 18.54% |
| Mar 2026 | $60.1M | 4.99% |
| Dec 2025 | $57.3M | 11.61% |
| 19 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | $963.6M |
| IONS Ionis Pharmaceuticals, Inc. compare | $874.1M |
| AXSM Axsome Therapeutics, Inc. compare | $865.3M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $669.5M |
| RYTM Rhythm Pharmaceuticals, Inc. | $280.7M |
| CYTK Cytokinetics, Incorporated compare | $113.3M |
| PRAX Praxis Precision Medicines, Inc. compare | $8.6M |
| ABVX Abivax SA Sponsored ADR compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RYTM
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement